Lexaria Bioscience (LEXX) Return on Capital Employed Growth (3y) (2021 - 2026)
Lexaria Bioscience (LEXX) Return on Capital Employed Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -356.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -516.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -4,078.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4,967.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5,777.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -9,445.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 109.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 513.00 |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | 7,511.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -99,254.00 |
| Feb 28, 2026 | -594,785.00 |
| Nov 30, 2025 | -12,355.00 |
| Aug 31, 2025 | -21,983.00 |
| May 31, 2025 | -11,193.00 |
| Feb 28, 2025 | -6,249.00 |
| Nov 30, 2024 | -2,400.00 |
| Aug 31, 2024 | -12,823.00 |
| May 31, 2024 | -8,346.00 |
| Feb 29, 2024 | 24,031.00 |
| Nov 30, 2023 | -26,140.00 |
| Aug 31, 2023 | -27,197.00 |
| May 31, 2023 | 102,388.00 |
| Feb 28, 2023 | 598,006.00 |
| Nov 30, 2022 | 98.00 |
| Aug 31, 2022 | 6,448.00 |
| May 31, 2022 | 4,314.00 |
| Feb 28, 2022 | 12,674.00 |
| Nov 30, 2021 | 17,867.00 |
| Aug 31, 2021 | 22,043.00 |